87 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이규용-
dc.date.accessioned2019-11-19T07:04:29Z-
dc.date.available2019-11-19T07:04:29Z-
dc.date.issued2017-01-
dc.identifier.citationJournal of Neurology and Neuroscience, v. 8, no. 1en_US
dc.identifier.issn2171-6625-
dc.identifier.urihttp://www.jneuro.com/neurology-neuroscience/reduction-of-mmp9-and-mif-levels-is-associated-with-the-beneficial-effects-of-cilostazol-in-the-patients-with-silent-brain-infarct.php?aid=18202-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/112409-
dc.description.abstractSilent brain infarcts (SBIs) are cerebral infarcts seen on brain computed tomography (CT) or magnetic resonance imaging (MRI) in the absence of any clinical symptoms of stroke. In a previous study, cilostazol was shown to prevent the appearance or progression of SBIs. The present study aimed to evaluate the possible mechanisms of cilostazol in its beneficial effects on patients with SBIs by serially measuring inflammation- and angiogenesisassociated biomarkers such as matrix metalloproteinase-9 (MMP-9), macrophage migration inhibitory factor(MIF), visceral fat–derived adipokine (visfatin), C-X-C motif ligand 12 (CXCL12), and vascular endothelial growth factor (VEGF). We consecutively enrolled 26 patients with SBIs. SBIs were interpreted by two neuroradiologists and two neurologists. MMP-9, MIF, visfatin, CXCL12, and VEGF were measured in fasting blood samples from these 26 patients and 10 healthy volunteers at baseline and after taking cilostazol (200 mg/day) for one week and for 3 months. Serum MMP-9 was higher in patients with SBIs than in healthy controls at baseline (p<0.05), and levels of MMP-9 and MIF decreased after taking cilostazol for 3 months (p<0.01). MMP-9 levels were also lower at 1 week in the cilostazol group (p<0.05). Cilostazol had no significant effect on the other inflammatory biomarkers such as visfatin, CXCL12 and VEGF. Cilostazol decreases the inflammatory biomarkers MMP-9 and MIF in patients with SBIs and it may contribute to its beneficial effects in these patients.en_US
dc.description.sponsorshipThis work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2015R1A2A2A04004865) and by a grant from the NanoBio R&D Program of the Korea Science and Engineering Foundation, funded by the Ministry of Education, Science and Technology (2007-04717).en_US
dc.language.isoenen_US
dc.publisheriMedPuben_US
dc.subjectSilent brain infarctsen_US
dc.subjectCilostazolen_US
dc.subjectMMP-9en_US
dc.subjectMIFen_US
dc.titleReduction of MMP-9 and MIF levels is associated with the beneficial effects of cilostazol in the patiens with silent brain infarctsen_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume8-
dc.identifier.doi10.21767/2171-6625.1000169-
dc.relation.page169-175-
dc.relation.journalJournal of Neurology and Neuroscience-
dc.contributor.googleauthorLee, Jin-Ho-
dc.contributor.googleauthorLee, Kyu-Yong-
dc.contributor.googleauthorPark, Hyun-Hee-
dc.contributor.googleauthorLee, Eun-Hye-
dc.contributor.googleauthorChoi, Na-Young-
dc.contributor.googleauthorHeo, Sung Hyuk-
dc.contributor.googleauthorChang, Dae-Il-
dc.contributor.googleauthorChoi, Hojin-
dc.contributor.googleauthorLee, Young Joo-
dc.contributor.googleauthorKoh, Seong-Ho-
dc.relation.code2017042696-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidkylee-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE